FindMyKOL
Clinical trialNCT01517035CompletedPhase 1/PHASE2Interventional

Improving Blood Stem Cell Collection and Transplant Procedures

SponsorNational Heart, Lung, and Blood Institute (NHLBI)Enrollment43Acute Lymphoblastic LeukemiaCLL (Chronic Lymphocytic Leukemia)CML (Chronic Myelogenous LeukemiaChronic Myelogenous LeukemiaMyelodysplastic Syndrome (MDS)
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Background: \- People who have some kinds of cancer can benefit from donated bone marrow stem cells. These stem cells help produce healthy bone marrow and slow or stop the spread of abnormal cells. However, stem cells transplants do not always work. Also, they may have serious side effects that can cause illness or death. The Bone Marrow Stem Cell Transplant Program is studying methods to make stem cell transplant procedures safer and more effective. Objectives: \- To test a new procedure that may improve the success and decrease the side effects of stem cell transplants. Eligibility: * Individuals 10 to 75 years of age who have a life-threatening illness that may require a stem cell transplant. * Healthy siblings who are able to provide stem cells for transplant. Design: * Participants will be screened with a medical history, physical exam, and blood and urine tests. * Donor procedures: * Stem cell donors will start by having apheresis to donate white blood cells. * Donors will receive filgrastim shots for 5 days to help move stem cells into the blood for collection. * Donors will have another round of apheresis to donate the stem cells for transplant. * Recipient procedures: * Before the transplant, recipients will have radiation twice a day for 3 days and chemotherapy for 7 days. * After the radiation and chemotherapy, recipients will receive the stem cells provided by the donor. * After the transplant, recipients will receive the white blood cells provided by the donor. * Recipients will be monitored closely for 4 months to study the success of the transplant. They will have more followup visits at least yearly thereafter. * Recipients will have a research apheresis prior to transplant and at 3 months.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

  • Minocher M Battiwalla, M.D.

    National Heart, Lung, and Blood Institute (NHLBI)

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • National Institutes of Health Clinical Center, 9000 Rockville Pike

    Bethesda, Maryland, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
13 Jan 2012
Primary completion
29 Mar 2017
Completion
29 Mar 2017
Last update posted
5 Jul 2018
Registered enrollment
43
Registry id
NCT01517035

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.